# 2025年12月31日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 由非专业健康工作者主导的症状干预对老年癌症患者急诊与住院利用的影响：一项随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41468027)
**期刊：** JAMA
**PMID：** 41468027
**DOI：** 10.1001/jama.2025.23403

### 第一部分 原文与翻译

**英文原标题：** A Lay Health Worker-Led Symptom Intervention and Acute Care Use in Older Adults With Cancer: A Randomized Clinical Trial.

> **英文摘要：**
> IMPORTANCE: Undertreated cancer symptoms are common among older adults, yet effective early identification and intervention remain limited.
> 
> OBJECTIVE: To determine whether lay health worker-led symptom assessment reduces acute care use among older adults with cancer.
> 
> DESIGN, SETTING, AND PARTICIPANTS: Multisite randomized clinical trial across 43 oncology clinics in California and Arizona conducted from November 2020 through October 2023 with 12 months of follow-up among Medicare Advantage beneficiaries aged 75 years or older with newly diagnosed, recurrent, or progressive cancer.
> 
> INTERVENTIONS: Participants were randomized 1:1 into a symptom assessment group (n = 200; usual care with lay health worker-led, telephone-based symptom assessments for 12 months using the Edmonton Symptom Assessment System) or a control group (n = 216; usual care alone), with planned enrollment of 200 in both groups. The lay health workers reviewed assessments with advanced practice practitioners who conducted interventions for symptoms rated 4 or greater or that increased by 2 points or more.
> 
> MAIN OUTCOMES AND MEASURES: Outcomes were determined a priori. The primary outcome was emergency department (ED) use and hospitalizations. Secondary outcomes were total costs, hospice, and, among decedents, acute care within 30 days of death and facility deaths.
> 
> RESULTS: Among 416 patients, the median age was 82 (range, 75-99) years; 219 (52.6%) were male; 171 (41.1%) had stage 4 disease; and 27 (6.4%) had recurrent disease. The mean risk adjustment factor score was 2.70 (SD, 1.77). Symptom assessment participants had 53% lower odds of ED use (61 [30.5%] vs 103 [47.7%] had ≥1 ED visit; adjusted odds ratio [OR], 0.47; 95% CI, 0.32-0.71), 68% lower odds of hospitalization (37 [18.5%] vs 86 [39.8%] had ≥1 hospitalization; OR, 0.32; 95% CI, 0.20-0.51), and lower mean total costs by $12 000 per participant (P = .01) than control group participants. Among 142 deceased participants (71 in each group), symptom assessment participants had 68% lower odds of ED use within 30 days of death (OR, 0.32; 95% CI, 0.12-0.88) and 75% lower odds of acute care facility death (OR, 0.25; 95% CI, 0.08-0.77).
> 
> CONCLUSIONS AND RELEVANCE: A lay health worker-led symptom assessment intervention may be a scalable approach to reduce acute care use.
> 
> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04463992.

> **中文摘要：**
> 【重要性】老年人中癌症症状治疗不足的情况十分普遍，但有效的早期识别与干预手段仍然有限。
> 
> 【研究目的】评估由非专业健康工作者主导的症状评估是否可降低老年癌症患者的急诊与住院使用率。
> 
> 【设计、场景与参与者】这是一项在加利福尼亚州和亚利桑那州43家肿瘤诊所中开展的多中心随机临床试验，时间为2020年11月至2023年10月，对年龄75岁及以上、享有联邦医保优势计划、且新发、复发或进展期癌症患者进行12个月的随访。
> 
> 【干预措施】受试者按1:1随机分组：症状评估组（n=200）接受常规治疗外加非专业健康工作者主导的、基于电话的为期12个月的症状评估（采用埃德蒙顿症状评估系统）；对照组（n=216）仅接受常规治疗。非专业健康工作者将评估结果与高级执业医师共同审查，并针对症状评分≥4或较前增加≥2分的情况实施干预。
> 
> 【主要结局与测量指标】研究预先设定了结局指标。主要结局为急诊（ED）使用和住院率。次要结局包括总费用、临终关怀使用，以及在死亡患者中，死亡前30天内的急诊利用和机构内死亡的发生率。
> 
> 【结果】共纳入416名患者，中位年龄82岁（范围75–99岁），219人（52.6%）为男性，171人（41.1%）为IV期疾病，27人（6.4%）为复发病例。平均风险调整因子评分为2.70（标准差1.77）。与对照组相比，症状评估组急诊使用的可能性降低53%（61人〔30.5%〕 vs 103人〔47.7%〕至少1次急诊；调整优势比0.47，95%置信区间0.32–0.71），住院的可能性降低68%（37人〔18.5%〕 vs 86人〔39.8%〕至少1次住院；优势比0.32，95%置信区间0.20–0.51），平均总费用每名参与者减少约12,000美元（P=0.01）。在死亡的142名参与者（每组各71人）中，症状评估组死亡前30天内急诊使用的可能性降低68%（优势比0.32，95%置信区间0.12–0.88），机构内死亡的可能性降低75%（优势比0.25，95%置信区间0.08–0.77）。
> 
> 【结论与意义】由非专业健康工作者主导的症状评估干预可能是一种可扩展的策略，用于减少老年癌症患者的急诊与住院利用。
> 
> 【试验注册】ClinicalTrials.gov 标识号：NCT04463992。

### 第二部分 AI 大师评价

该研究通过多中心随机对照试验验证了由非专业健康工作者主导的电话症状评估在老年癌症患者中可显著减少急诊与住院使用。方法学设计严谨、样本量充分，结果显示该模式在降低医疗成本和改善临终护理方面具有潜在推广价值。其创新点在于将社区层级人力资源整合入症状管理流程，实现可扩展的干预模式。但研究局限于美国特定地区，未来需验证其在其他健康体系中的可行性与成本效益。

---

## 2. 由基层健康工作者主导的症状干预与老年癌症患者急诊医疗利用：研究综述

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41468010)
**期刊：** JAMA
**PMID：** 41468010
**DOI：** 10.1001/jama.2025.24267

### 第一部分 原文与翻译

**英文原标题：** A Lay Health Worker-Led Symptom Intervention and Acute Care Use in Older Adults With Cancer: Research Summary.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该研究摘要未提供具体内容，但从标题推测，研究可能探讨由基层健康工作者主导的症状管理干预对老年癌症患者急性医疗服务使用情况的影响。此类干预旨在通过社区层面的健康教育和症状监测，减少不必要的急诊和住院使用，改善患者生活质量。研究可能采用随机对照或队列设计来量化急诊就诊率的变化。其创新性在于将非专业健康工作者纳入癌症照护体系，但潜在局限性在于干预一致性和可推广性需进一步验证。

---

## 3. 一种可扩展的模型以改善老年人癌症护理——低投入，高影响。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41468009)
**期刊：** JAMA
**PMID：** 41468009
**DOI：** 10.1001/jama.2025.15302

### 第一部分 原文与翻译

**英文原标题：** A Scalable Model to Improve Cancer Care for Older Adults-Lo-Fi, High Impact.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究提出了一种旨在提升老年癌症患者护理质量的可扩展模型，强调以较低复杂度和资源投入实现显著的临床效果。虽然摘要缺失，但从标题可推断，研究核心在于优化护理流程、提升服务可及性与效率。该模型的“低投入、高影响”理念具有现实意义，可为资源有限的医疗体系提供创新思路。其局限可能在于缺乏对不同癌症类型与照护环境的适应性验证，因此仍需进一步临床验证与长期随访。

---

## 4. 出版者更正：在人类遗传变异在小鼠基因组中的计算预测

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41466062)
**期刊：** Nature biotechnology
**PMID：** 41466062
**DOI：** 10.1038/s41587-025-02991-4

### 第一部分 原文与翻译

**英文原标题：** Publisher Correction: Computational prediction of human genetic variants in the mouse genome.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文为出版社更正声明，指向一项关于利用计算方法预测小鼠基因组中的人类遗传变异的研究。虽然正文未提供摘要，但可推测原文聚焦于跨物种基因组比对与变异注释算法的准确性问题。此更正体现了出版方对研究结果与数据一致性的严谨态度，确保科研记录的可靠性与透明性。

---

## 5. 人源诱导多能干细胞来源NK细胞作为“现成型”细胞治疗的挑战与机遇

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41462483)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41462483
**DOI：** 10.1186/s13046-025-03558-6

### 第一部分 原文与翻译

**英文原标题：** Challenges and opportunities of human iPSC-derived NK as "Off-the-shelf" cellular therapies.

> **英文摘要：**
> The field of human induced pluripotent stem cell (hiPSC)-derived cell therapies is rapidly advancing, offering a promising "off-the-shelf" approach for treating both solid and hematologic malignancies. Among these, hiPSC-derived Natural Killer (NK) cell therapies have gained significant traction, with several currently in clinical trials and development. NK cell-based immunotherapy has emerged as a safe and effective strategy for patients with advanced leukemia, and ongoing research is focused on optimizing its accessibility, scalability, and efficacy. A key advantage of hiPSC-derived NK cells is their genetic susceptibility, allowing for targeted enhancements in fitness, metabolism, specificity, and cytotoxicity. This overcomes the donor-dependent variability that limits autologous and allogeneic NK cell therapies, which often struggle with expansion and functional consistency. Despite their promise, hiPSC-derived NK cells present unique manufacturing challenges, requiring precise optimization to ensure reproducibility, safety, and clinical-grade scalability. In this review, we will explore what we believe to be the most impactful genetic engineering strategies to enhance hiPSC-derived NK cell function. Additionally, we will also discuss the major hurdles challenging widespread clinical adoption, including licensing constraints, production yield, regulatory ambiguities, and the complexities of multi-step genetic engineering and safety validation. Finally, we will outline the emerging therapeutic pipelines from leading biotech companies, providing a valuable and up-to-date overview of the future landscape of hiPSC-derived NK cell therapy.

> **中文摘要：**
> 人源诱导多能干细胞（hiPSC）来源的细胞治疗领域正快速发展，为治疗实体瘤和血液恶性肿瘤提供了一个具有前景的“现成型”治疗途径。在这些策略中，hiPSC来源的自然杀伤（NK）细胞疗法已获得显著关注，多个项目正处于临床试验和研发阶段。基于NK细胞的免疫治疗已被证明是治疗晚期白血病患者的一种安全有效策略，而持续的研究正致力于优化其可及性、可扩展性及疗效。hiPSC来源NK细胞的一个关键优势在于其遗传可塑性，使得在细胞适应性、代谢、特异性及细胞毒性方面可进行靶向增强。这一特性克服了自体及异体NK细胞疗法受供体依赖性差异影响的问题，而后者常在扩增性与功能一致性方面面临挑战。尽管前景可期，hiPSC来源NK细胞的生产依然存在独特的制造难题，需要精确优化以确保可重复性、安全性及符合临床级标准的可扩展性。在本综述中，我们将探讨认为最具影响力的遗传工程策略，以增强hiPSC来源NK细胞的功能。此外，我们还将讨论阻碍其广泛临床应用的主要障碍，包括知识产权许可限制、产量问题、监管模糊以及多步骤基因工程与安全性验证的复杂性。最后，我们将概述领先生物技术公司正在推进的创新治疗管线，提供关于hiPSC来源NK细胞治疗未来格局的有价值且前沿的综述。

### 第二部分 AI 大师评价

该综述系统地解析了人源诱导多能干细胞来源NK细胞在“现成型”免疫治疗领域的研究现状与未来方向。作者强调其遗传可塑性带来的功能优化潜力，并指出生产标准化、安全性验证及监管框架的不确定性是主要瓶颈。文章的创新性在于整合最新的基因工程策略与产业化管线，呈现了技术、法规与临床转化的多维挑战。总体而言，该研究为NK细胞治疗的可扩展应用提供了重要的概念性与实践性参考。

---

## 6. 更正：通过抗体治疗双重靶向 HER 家族受体以克服西妥昔单抗获得性耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41462474)
**期刊：** Molecular cancer
**PMID：** 41462474
**DOI：** 10.1186/s12943-025-02531-3

### 第一部分 原文与翻译

**英文原标题：** Correction: Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文为对原始研究的更正声明，研究主题聚焦于通过双重靶向 HER 家族受体的抗体疗法来克服西妥昔单抗的获得性耐药问题。尽管当前无可用摘要，但可推断其研究意义在于探索联合或双靶策略以提高抗 EGFR 治疗的持久疗效。相关研究对理解耐药机制及优化靶向治疗策略具有明确的转化医学价值。

---

## 7. TCF3 激活超级增强子驱动的 TRIB2 过度表达以抑制铁死亡并促进肝母细胞瘤增殖

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41462308)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41462308
**DOI：** 10.1186/s13046-025-03587-1

### 第一部分 原文与翻译

**英文原标题：** TCF3 activates super-enhancer-driven TRIB2 overexpression to suppress ferroptosis and promote hepatoblastoma proliferation.

> **英文摘要：**
> BACKGROUND: Hepatoblastoma (HB) is the most common pediatric liver malignancy with an increasing incidence. However, the functional roles of 3D chromatin organization, epigenetic regulatory factors, and transcriptional reprogramming in HB pathogenesis remain poorly understood.
> 
> METHODS: ​Integrated multi-omics analyses of HB and matched non-tumor tissues were performed, including Hi-C, H3K27ac CUT&Tag, ATAC-seq, and RNA-seq, to construct high-resolution 3D epigenomic maps and identify genes interacting with HB-specific super-enhancers (SEs). Functional assays of identified targets were conducted in cell lines and animal models. The regulatory mechanisms of SEs and upstream transcription factors (TFs) were investigated using CRISPRi-dCas9, 3C-qPCR, ChIP-qPCR, and luciferase reporter assays.
> 
> RESULTS: Comprehensive analysis identified TRIB2 as an HB-specific SE-associated oncogene. Functionally, TRIB2 promoted cell proliferation and accelerated tumor growth both in vitro and in vivo. Patients with high TRIB2 expression exhibited advanced PRETEXT stage and metastasis. Mechanistically, TCF3 directly bound to both the TRIB2-SE and its promoter, promoting TRIB2 overexpression. Moreover, TRIB2 conferred resistance to ferroptosis by disrupting KEAP1-mediated ubiquitination of NRF2, thereby stabilizing NRF2 protein and enhancing antioxidant responses. The TCF3-TRIB2-NRF2 axis showed significant co-expression in HB tissues, effectively distinguished HB from normal liver tissues, and was associated with poorer overall survival.
> 
> CONCLUSIONS: Our findings reveal that TCF3 and SE mediate TRIB2 overexpression to inhibit ferroptosis via the KEAP1-NRF2 pathway and drive HB pathogenesis, providing potential diagnostic and prognostic markers for HB.

> **中文摘要：**
> 背景：肝母细胞瘤（HB）是最常见的儿童肝脏恶性肿瘤，且其发病率呈上升趋势。然而，三维染色质结构、表观遗传调控因子及转录重编程在HB发病机制中的功能作用尚不明确。
> 
> 方法：对HB组织及匹配的非肿瘤组织进行了整合性多组学分析，包括Hi-C、H3K27ac CUT&Tag、ATAC-seq和RNA-seq，以构建高分辨率的三维表观基因组图谱，并鉴定与HB特异性超级增强子（SE）相互作用的基因。在细胞系和动物模型中对筛选出的靶基因进行了功能实验。采用CRISPRi-dCas9、3C-qPCR、ChIP-qPCR和荧光素酶报告实验探讨了SE及上游转录因子的调控机制。
> 
> 结果：综合分析鉴定出TRIB2为HB特异性的SE相关癌基因。在功能层面，TRIB2可促进细胞增殖并加速体内外肿瘤生长。高TRIB2表达患者表现出更高的PRETEXT分期和转移倾向。从机制上看，TCF3可直接结合TRIB2-SE及其启动子，促进TRIB2过度表达。此外，TRIB2通过破坏KEAP1介导的NRF2泛素化，稳定NRF2蛋白并增强抗氧化反应，从而赋予抗铁死亡能力。TCF3-TRIB2-NRF2轴在HB组织中表现出显著的共表达，能够有效区分HB与正常肝组织，并与较差的总体生存期相关。
> 
> 结论：本研究发现，TCF3与超级增强子共同介导TRIB2的过度表达，通过KEAP1-NRF2通路抑制铁死亡并驱动HB发病，为HB提供了潜在的诊断及预后标志物。

### 第二部分 AI 大师评价

该研究通过多组学整合分析系统揭示了肝母细胞瘤中超级增强子调控网络的关键作用，确定了TRIB2为由TCF3驱动的SE关联癌基因。研究团队利用Hi-C、CUT&Tag等前沿技术构建了高分辨率三维表观基因组图谱，并在机制上明确了TCF3-TRIB2-NRF2轴如何通过阻断铁死亡促进肿瘤增殖。该工作在阐明HB的表观遗传调控机制方面具有创新性，并为临床诊断与预后评估提供了新靶点，但仍需进一步验证其临床转化价值。

---

## 8. 联合线粒体靶向基因治疗与化疗治疗三阴性乳腺癌

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41462289)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41462289
**DOI：** 10.1186/s13046-025-03572-8

### 第一部分 原文与翻译

**英文原标题：** Combine mitochondrial-targeted gene therapy and chemotherapy to treat triple-negative breast cancer.

> **英文摘要：**
> Triple-negative breast cancer (TNBC) is an aggressive and chemotherapy resistant subtype with high metastatic potential and frequent recurrence after standard treatment. While poly (ADP-ribose) polymerase inhibitors (PARPi) show efficacy in TNBCs with DNA repair deficiencies, only ~ 20% of patients respond, underscoring the need for more effective therapies. Mitochondria, as central regulators of cancer cell survival, present a compelling therapeutic target. Here, we introduce a novel gene-chemotherapy combining our mitochondria-targeted luminoptogenetics technology (cmLumiOpto), which directly disrupts mitochondrial membrane potential and induces cancer cell death, with PARPi to enhance TNBC treatment outcomes. To achieve targeted delivery, we conjugated a high-affinity anti-CD276 monoclonal antibody (mAb) that selectively binds human and mouse TNBCs to an exosome-associated adeno-associated virus (mAb-Exo-AAV). In vitro studies confirmed successful transfection, internalization, and functional expression of cmLumiOpto, leading to significantly enhanced cytotoxicity when combined with PARPi. In vivo, the combination therapy achieved a 95-100% reduction in tumor burden, suppressed patient-derived xenograft growth, and inhibited metastasis in four TNBC mouse models. Post-treatment analyses confirmed mitochondrial depolarization, downregulation of DNA replication, cytokine upregulation, and immune cell infiltration in tumor. These findings highlight the potential of mitochondria-targeted gene therapy combined with chemotherapy as a powerful and innovative strategy for TNBC treatment.

> **中文摘要：**
> 三阴性乳腺癌（TNBC）是一种侵袭性强且对化疗具有耐药性的亚型，具有高度转移潜能，并在标准治疗后常见复发。尽管多聚（ADP-核糖）聚合酶抑制剂（PARPi）在DNA修复缺陷的TNBC患者中显示出一定疗效，但仅约20%的患者有反应，凸显了开发更有效疗法的迫切需求。线粒体作为癌细胞存活的核心调控者，是一个极具吸引力的治疗靶点。本研究提出了一种新型的基因-化疗联合策略，将我们开发的线粒体靶向光遗传技术（cmLumiOpto）——能够直接破坏线粒体膜电位并诱导癌细胞死亡——与PARPi相结合，以增强TNBC的治疗效果。为实现靶向递送，我们将高亲和力的抗CD276单克隆抗体（mAb），该抗体可特异性结合人和小鼠的TNBC细胞，偶联至外泌体相关的腺相关病毒（mAb-Exo-AAV）。体外研究证实了cmLumiOpto的成功转染、内化及功能性表达，并在与PARPi联合时显著增强了细胞毒性。体内实验中，该联合疗法在四种TNBC小鼠模型中实现了肿瘤负荷减少95–100%，抑制了患者来源的异种移植肿瘤生长及肿瘤转移。治疗后分析显示，肿瘤细胞的线粒体去极化、DNA复制下调、细胞因子上调及免疫细胞浸润均得到验证。这些结果表明，线粒体靶向基因治疗与化疗的联合策略是一种具有强大潜力和创新意义的TNBC治疗途径。

### 第二部分 AI 大师评价

该研究针对三阴性乳腺癌治疗中的化疗耐药问题，提出了将线粒体靶向基因疗法与PARP抑制剂相结合的新策略。研究团队利用抗CD276抗体介导的外泌体-AAV系统实现靶向递送，并通过线粒体光遗传技术有效诱导癌细胞死亡。体内外实验均显示显著的抗肿瘤效果和免疫活化反应，肿瘤负荷降低达近乎完全清除。此研究在疗法设计上具有高度创新性，为难治型乳腺癌提供新的治疗思路，但其临床转化与安全性仍需进一步验证。

---

## 9. 通过血管周微环境与循环内皮祖细胞的相互作用实现打印血管移植物的快速内皮化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41462027)
**期刊：** Nature communications
**PMID：** 41462027
**DOI：** 10.1038/s41467-025-68075-8

### 第一部分 原文与翻译

**英文原标题：** Rapid endothelialization of printed vascular grafts by perivascular niche-circulating endothelial progenitors crosstalk.

> **英文摘要：**
> Successful regeneration of small-diameter vascular grafts requires rapid endothelialization to ensure patency. However, effectively recruiting circulating endothelial progenitor cells to achieve this remains a significant challenge. Here we show that accelerating the growth of adventitia into vascular grafts promotes fallout endothelialization on the blood-contacting surface. We engineered Micro-Nano structured Vascular Grafts (MnVGs) using high-resolution electrohydrodynamic (EHD) printing and electrostatic spinning. When implanted in rabbits, MnVGs rapidly regenerated neo-adventitia within the highly porous graft walls and achieved endothelialization as early as 2 weeks postoperatively, resulting in 90% patency rate (18/20). The regenerated arteries closely matched native vessels in structure and function. Mechanistically, we discovered that lymphatic endothelial cells enriched in the neoadventitia, were identified as the main contributors to the early recruitment of CD93+ ECs, which ultimately constituted the majority of the endothelium. Thus, MnVGs represent a potential strategy to preventing thrombosis in replacement of small caliber arteries.

> **中文摘要：**
> 小直径血管移植物的成功再生需要快速的内皮化以确保通畅性。然而，如何有效招募循环内皮祖细胞以实现这一目标仍是重大挑战。在此，我们展示了加速血管外膜向移植物内生长可促进血液接触面上的沉积性内皮化。我们利用高分辨率静电流体动力（EHD）打印与静电纺丝技术构建了微纳结构血管移植物（MnVGs）。当植入兔体内时，MnVGs 能在高孔隙率移植物壁内快速再生新生外膜，并在术后仅两周即可实现内皮化，通畅率达 90%（18/20）。再生的动脉在结构和功能上与天然血管高度一致。在机制上，我们发现富集于新生外膜中的淋巴内皮细胞是早期招募 CD93+ 内皮细胞（ECs）的主要贡献者，而这些细胞最终构成了内皮的大部分。因此，MnVGs 提供了一种在小口径动脉替代中防止血栓形成的潜在策略。

### 第二部分 AI 大师评价

本文针对小直径血管移植物难以实现快速内皮化的问题，利用高分辨率EHD打印与静电纺丝技术构建微纳结构血管移植物，实现了血管外膜快速生长并促进内皮覆盖。动物实验表明其在两周内即可形成功能性内皮层并保持高通畅率。研究揭示了新生外膜中淋巴内皮细胞在招募CD93+内皮细胞中的关键作用，阐明了内皮化加速的细胞机制。该成果在促进小口径血管替代及防止血栓形成方面具有重要创新性，但其长期安全性及在大动物模型中的适用性仍需进一步验证。

---

## 10. 应激通过催产素-Gαi 依赖性星形胶质细胞重塑来调控杏仁核中的神经元反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41462022)
**期刊：** Nature communications
**PMID：** 41462022
**DOI：** 10.1038/s41467-025-68114-4

### 第一部分 原文与翻译

**英文原标题：** Stress induces oxytocin-Gαi-dependent remodeling of astrocytes to shape neuronal response in the amygdala.

> **英文摘要：**
> Anticipated reactions to stressful situations are vital for the survival and well-being of organisms, and abnormal reactions results in stress-related disorders. The neuropeptide oxytocin is a key modulator ensuring well-adapted stress responses. Oxytocin acts on both neurons and astrocytes, but the molecular and cellular mechanisms mediating stress response remain poorly understood. Here, we focus on the amygdala, a crucial hub that integrates and processes sensory information through oxytocin-dependent mechanisms. Using an acute stress paradigm in mice, genetic and pharmacological manipulations combined with proteomic, morphological, electrophysiological and behavioral approaches, we reveal that oxytocinergic modulation of the freezing response to stress is mediated by transient Gαi-dependent retraction of astrocytic processes, followed by enhanced neuronal sensitivity to extracellular potassium in the amygdala. Our findings elucidate a pivotal role for astrocytes morphology-dependent modulation of brain circuits that is required for proper anticipated behavioral response to stressful situations.

> **中文摘要：**
> 对压力情境的预期反应对生物体的生存与健康至关重要，而异常的反应则会导致与压力相关的障碍。神经肽催产素是确保良好适应性应激反应的关键调节因子。催产素作用于神经元和星形胶质细胞，但介导应激反应的分子和细胞机制仍不甚明了。在本研究中，我们聚焦于杏仁核这一通过催产素依赖性机制整合和处理感觉信息的重要枢纽。利用小鼠急性应激模型，通过遗传学和药理学操控，结合蛋白质组学、形态学、电生理学及行为学方法，我们揭示了催产素能调节应激冻结反应的机制依赖于星形胶质细胞突起的短暂 Gαi 依赖性收缩，随后导致杏仁核神经元对细胞外钾离子的敏感性增强。我们的研究结果阐明了星形胶质细胞形态依赖性地调节脑环路的关键作用，这一机制对于生物体对压力情境的恰当预期行为反应是必需的。

### 第二部分 AI 大师评价

该研究聚焦催产素在杏仁核应激反应调控中的作用，揭示了其通过 Gαi 依赖性调节星形胶质细胞结构变化影响神经元功能的机制。研究结合遗传、药理及多模态实验手段，从形态、电生理至行为层面系统验证了这一机制。结果揭示了星形胶质细胞形态动态在应激行为调控中的关键地位，拓展了催产素信号调节神经环路的理解。其创新在于首次将催产素的胶质—神经调控与应激行为联系起来，但研究仍需在慢性应激模型与人类相关性上进一步验证。

---

## 11. KRT15肿瘤细胞分泌的CCL20促进三级淋巴样结构形成并增强HPV阳性头颈鳞状细胞癌对抗PD-1治疗的反应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41462011)
**期刊：** Cell death & disease
**PMID：** 41462011
**DOI：** 10.1038/s41419-025-08359-5

### 第一部分 原文与翻译

**英文原标题：** CCL20 secreted by KRT15 tumor Cells promotes tertiary lymphoid structure formation and enhances anti-PD-1 therapy response in HPVHNSCC.

> **英文摘要：**
> Tertiary lymphoid structures (TLS) are associated with an improved response to Immune checkpoint therapy (ICT) in head and neck squamous cell carcinoma (HNSCC). Human papillomavirus (HPV) infection constitutes a high-risk factor for HNSCC carcinogenesis. However, its role in TLS formation has yet to be elucidated. Herein, immunohistochemical (IHC) analysis from 59 HNSCC patients revealed a higher prevalence of mature TLS in HPV-positive (HPV) HNSCC compared to HPV-negative (HPV) cases. Furthermore, integrated analysis of single-cell RNA sequencing, spatial transcriptomics, and RNA-seq data indicated that TLS-positive tumors were characterized by an expanded population of KRT15 tumor cells in HNSCC. IHC and cytological experiments confirmed upregulation of KRT15 in HPVHNSCC tumor cells, which also showed high expression of cancer stem cell marker genes. These KRT15 stem-like tumor cells specifically secreted CCL20, which was related to the infiltration of TLS-associated immune cells in HPVHNSCC. Murine models confirmed that CCL20 treatment promoted TLS formation and enhanced the efficacy of anti-PD-1 therapy. Multiplex immunofluorescence showed that TLS provided specialized microenvironments that supported the proliferation of CD39PD-1CD8T cells. Collectively, our findings proposed that CCL20 secreted by HPV-infected KRT15 tumor cells promoted TLS formation, thereby enhancing anti-PD-1 therapy responses in HPVHNSCC. This study provides mechanistic insights into HPV-mediated TLS development and supports precision immunotherapeutic strategies for HNSCC.

> **中文摘要：**
> 三级淋巴样结构（TLS）与头颈鳞状细胞癌（HNSCC）对免疫检查点治疗（ICT）的改善反应相关。人乳头瘤病毒（HPV）感染是HNSCC发生的高风险因素。然而，其在TLS形成中的作用尚未阐明。本研究中，对59例HNSCC患者进行的免疫组织化学（IHC）分析显示，与HPV阴性病例相比，HPV阳性HNSCC中成熟TLS的发生率更高。此外，对单细胞RNA测序、空间转录组学及RNA测序数据的综合分析表明，TLS阳性肿瘤在HNSCC中表现出KRT15肿瘤细胞群体的扩增。IHC及细胞学实验进一步证实，在HPV相关HNSCC的肿瘤细胞中KRT15上调，这些细胞还高表达癌症干细胞标志基因。这些表现出干样特征的KRT15肿瘤细胞特异性分泌CCL20，与HPV相关HNSCC中TLS相关免疫细胞的浸润相关。小鼠模型验证CCL20处理可促进TLS形成并增强抗PD-1疗法的疗效。多重免疫荧光实验显示，TLS可提供支持CD39PD-1CD8T细胞增殖的特化微环境。综上所述，我们的研究提出，HPV感染的KRT15肿瘤细胞分泌的CCL20可促进TLS形成，从而增强HPV阳性HNSCC对抗PD-1疗法的应答。本研究为HPV介导的TLS形成机制提供了新的见解，并支持HNSCC的精准免疫治疗策略。

### 第二部分 AI 大师评价

该研究系统阐明了HPV阳性头颈鳞癌中KRT15肿瘤细胞通过分泌CCL20促进三级淋巴样结构形成的机制。研究采用免疫组化、单细胞转录组、空间转录组及动物模型等多层证据链方法，揭示CCL20在改善抗PD-1疗法反应中的关键作用。其创新点在于首次将特定肿瘤干样细胞与TLS形成和免疫治疗敏感性联系起来，为HPV相关HNSCC的精准免疫治疗提供新靶点。但仍需进一步临床验证CCL20信号通路在患者群体中的可预测性与治疗价值。

---

## 12. PDZRN4通过抑制泛素介导的HIF-1A降解抑制肺腺癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41461926)
**期刊：** Oncogene
**PMID：** 41461926
**DOI：** 10.1038/s41388-025-03670-z

### 第一部分 原文与翻译

**英文原标题：** PDZRN4 suppresses lung adenocarcinoma progression via inhibiting ubiquitin-mediated HIF-1A degradation.

> **英文摘要：**
> Indolent lung cancer is characterized by slow progression, and the patient may die of other causes before it becomes symptomatic. The increasing usage of lung cancer screening technologies has increased the detection of early-stage cancers, improved survival, and reduced mortality, but it also brings overdiagnosis or overtreatment for indolent lung cancer patients. In this study, we performed high-throughput whole-exome sequencing in lung adenocarcinoma (LUAD) patients with a tumor doubling time of more than 600 days (the indolent group) and another group with a tumor doubling time of less than 30 days (the aggressive group). We identified a novel germline variation in PDZRN4, rs74955204 (p.G121E, c.362 G > A) in the indolent group. The rs74955204 variant resulted in upregulated PDZRN4 expression and was positively correlated with the survival of LUAD patients. We confirmed that overexpression of PDZRN4 inhibits the ubiquitylation of HIF-1A mediated by TRIM28, thus activating HIF-1A-IGFBP3 signaling to promote apoptosis, and inducing NDRG1 to inhibit EGFR-AKT signaling, restricting lung cancer cell growth in vitro and in vivo. With the EGFR-driven lung cancer mouse model as an example, we found that PDZRN4 knockout promoted, whereas PDZRN4 overexpression suppressed LUAD growth in vivo. In addition, recombinant PDZRN4 or screened small molecules retinoic acid showed potent inhibitory effects on EGFR-driven LUAD growth and amelioration of osimertinib resistance. Overall, our findings suggest that targeted PDZRN4 is a potential therapeutic strategy for treating LUAD. Examination of PDZRN4 rs74955204 variant may be an effective approach for the early detection of indolent lung cancer and to avoid overdiagnosis. Graphical Abstract: Germline variation rs74955204 (p.G121E, c.362 G > A) in PDZRN4 significantly upregulated PDZRN4 expression and resulted in indolent growth of LUAD. Overexpressed PDZRN4 inhibits the ubiquitylation of HIF-1A by TRIM28, activating HIF-1A-IGFBP3 signaling to promote apoptosis, and inducing NDRG1 to inhibit EGFR-AKT signaling, thus restricting lung cancer cell growth.

> **中文摘要：**
> 惰性肺癌的特征是进展缓慢，患者可能在出现症状之前因其他原因死亡。肺癌筛查技术的广泛应用提高了早期癌症的检出率，改善了生存率并降低了死亡率，但同时也为惰性肺癌患者带来了过度诊断或过度治疗的问题。在本研究中，我们对肿瘤倍增时间超过600天的肺腺癌（LUAD）患者（惰性组）以及肿瘤倍增时间少于30天的另一组患者（侵袭性组）进行了高通量全外显子测序。我们在惰性组中鉴定出PDZRN4基因的一个新型种系变异rs74955204（p.G121E, c.362 G > A）。该rs74955204变异导致PDZRN4表达上调，并与LUAD患者的生存率呈正相关。我们证实，PDZRN4过表达可抑制由TRIM28介导的HIF-1A泛素化，从而激活HIF-1A-IGFBP3信号通路以促进细胞凋亡，并诱导NDRG1抑制EGFR-AKT信号通路，从而在体内外限制肺癌细胞生长。以EGFR驱动的肺癌小鼠模型为例，我们发现PDZRN4敲除促进，而PDZRN4过表达抑制了LUAD在体内的生长。此外，重组PDZRN4或筛选的小分子维甲酸对EGFR驱动的LUAD生长表现出显著的抑制作用，并改善了奥希替尼耐药性。总体而言，我们的研究结果提示，靶向PDZRN4可能是一种治疗LUAD的潜在策略。检测PDZRN4 rs74955204变异可能是早期发现惰性肺癌并避免过度诊断的有效方法。图形摘要：PDZRN4中的种系变异rs74955204（p.G121E, c.362 G > A）显著上调PDZRN4表达，导致LUAD惰性生长。PDZRN4过表达通过抑制TRIM28介导的HIF-1A泛素化，激活HIF-1A-IGFBP3信号以促进凋亡，并诱导NDRG1抑制EGFR-AKT信号，从而限制肺癌细胞生长。

### 第二部分 AI 大师评价

该研究聚焦于惰性肺腺癌的分子机制，通过全外显子测序发现PDZRN4基因的种系变异与肿瘤缓慢生长及患者更好生存相关。作者揭示了PDZRN4通过抑制TRIM28介导的HIF-1A泛素化，调控HIF-1A-IGFBP3和NDRG1-EGFR-AKT信号通路，从而抑制肿瘤生长的机制。实验涵盖体内外功能验证及药物干预，创新性在于提出PDZRN4作为潜在治疗靶点及预测惰性癌的生物标志物。然而，仍需更多临床验证以确立PDZRN4在不同人群中的普适性和治疗可行性。

---

## 13. 一种新型抗结核药物显示出显著的临床疗效和良好的安全性特征：一项开放标签、随机对照、多中心、Ⅱa期临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41461639)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41461639
**DOI：** 10.1038/s41392-025-02517-z

### 第一部分 原文与翻译

**英文原标题：** A novel antituberculosis agent exhibits potent clinical efficacy and good safety profile: an open-label, randomized-controlled, multicenter, phase 2a trial.

> **英文摘要：**
> Tuberculosis (TB) is a contagious disease that threatens human health worldwide. Combination chemotherapy is usually recommended for this disease. Recently, 2 nitroimidazole-based agents, namely, delamanid and pretomanid, have been approved by regulatory agencies. JDB0131 is a novel, structurally optimized third-generation nitroimidazole antituberculosis agent that incorporates the advantages of earlier compounds. This multicenter, prospective, randomized phase 2a trial was conducted to evaluate its efficacy and safety in patients with tuberculosis (NCT06224036). In total, 52 patients with newly diagnosed TB were recruited. JDB0131 was tested in a dose escalation manner (cohort 1: 100 mg bid, cohort 2: 200 mg qd, and cohort 3: 200 mg bid). For comparison, delamanid (100 mg bid) and classic fixed-dose combination (FDC) regimens were included as controls. The primary endpoint was logarithmic changes in the number of colony formation units (CFUs) in the solid media culture of sputum TB (log10 CFU). The early bactericidal activity (EBA) of JDB0131 was better than that of delamanid. During the time interval between days 0 and 14, JDB0131 at a dose of 200 mg bid (cohort 3) showed superior efficacy over delamanid. At the end of drug intervention (day 14), JDB0131 (all 3 dose levels) achieved superior time to positivity (TTP) over delamanid. Ninety-one adverse events (AEs), including no serious AEs, were attributed to JDB0131 in 30 patients. This trial identified a promising new drug for the increasing TB burden worldwide.

> **中文摘要：**
> 结核病（TB）是一种对全球人类健康构成威胁的传染性疾病。通常推荐采用联合化疗治疗该病。近期，两种基于硝基咪唑结构的药物——德拉马尼（delamanid）和普利马尼（pretomanid）已获监管机构批准。JDB0131是一种新型的、经过结构优化的第三代硝基咪唑类抗结核药物，融合了早期化合物的优势。本项多中心、前瞻性、随机Ⅱa期临床试验旨在评估其在结核病患者中的疗效与安全性（NCT06224036）。共纳入52例新诊断结核病患者。JDB0131采用剂量递增设计进行测试（队列1：100 mg 每日两次，队列2：200 mg 每日一次，队列3：200 mg 每日两次）。为进行比较，将德拉马尼（100 mg 每日两次）及经典的固定剂量联合方案（FDC）作为对照。主要终点为痰液结核菌固体培养中菌落形成单位（CFU）数量的对数变化（log10 CFU）。JDB0131的早期杀菌活性（EBA）优于德拉马尼。在0至14天期间，JDB0131 200 mg 每日两次（队列3）的疗效显著优于德拉马尼。在药物干预结束时（第14天），JDB0131（全部三种剂量）在阳性时间（TTP）方面均优于德拉马尼。共有91例不良事件（AEs）归因于JDB0131，涉及30名患者，且无严重不良事件。本研究发现了一种有望应对全球日益加重结核负担的潜在新药。

### 第二部分 AI 大师评价

该研究旨在评估一种新型第三代硝基咪唑类抗结核药物JDB0131的临床疗效与安全性。通过多中心、随机、开放标签Ⅱa期试验设计，比较其与德拉马尼及固定剂量联合方案的疗效。结果显示，JDB0131在14天内表现出显著优于德拉马尼的早期杀菌活性和阳性时间改善，且安全性良好。研究为结核病治疗提供了新的分子候选药物，尽管样本量较小且随访周期较短，但其临床前景值得进一步验证。

---

## 14. 靶向TRIM15介导的Axin1去聚合可抑制Wnt信号并抑制结直肠癌生长

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41461634)
**期刊：** Cell death & disease
**PMID：** 41461634
**DOI：** 10.1038/s41419-025-08400-7

### 第一部分 原文与翻译

**英文原标题：** Targeting TRIM15-mediated Axin1 depolymerization suppresses Wnt signaling and inhibits colorectal cancer growth.

> **英文摘要：**
> Axin1 plays a critical role in regulating the Wnt/β-catenin signaling pathway and cancer progression, and its polymerization is indispensable for the assembly of the β-catenin destruction complex. However, the mechanisms that control Axin1 polymerization are limited. Here, we reveal that TRIM15 interferes with the polymerization of Axin1, thereby promoting Wnt activation and colorectal cancer growth. Mechanistically, TRIM15 strongly interacts with Axin1 through its coiled-coil domain to disrupt the polymerization among Axin1 molecules. Manipulation of TRIM15 expression dramatically weakens Wnt signaling, cell proliferation, and tumor growth. Furthermore, conditional genetic ablation of Trim15 in mice inhibits tumor formation in both AOM/DSS-induced and Apc colorectal cancer models. Notably, TRIM15 is also a Wnt target gene that forms a positive feedback loop in colon cancer cells. TRIM15 is highly expressed and is positively associated with β-catenin in colorectal cancer. More importantly, the simultaneous increase in Axin1 protein levels and its polymerization can synergistically induce apoptosis. Together, our study uncovers an important regulatory mechanism of Axin1 polymerization and implies that targeting TRIM15 provides a therapeutic strategy for colorectal cancer based on inhibiting Wnt signaling.

> **中文摘要：**
> Axin1在调控Wnt/β-连环蛋白信号通路及癌症进展中发挥关键作用，其聚合对于β-连环蛋白降解复合物的组装至关重要。然而，控制Axin1聚合的机制仍然有限。在本研究中，我们揭示TRIM15可干扰Axin1的聚合，从而促进Wnt信号激活及结直肠癌的生长。在机制上，TRIM15通过其卷曲螺旋结构域与Axin1强烈相互作用，破坏Axin1分子之间的聚合。调控TRIM15的表达可显著削弱Wnt信号、细胞增殖及肿瘤生长。此外，在小鼠中有条件敲除Trim15可在AOM/DSS诱导型及Apc结直肠癌模型中抑制肿瘤形成。值得注意的是，TRIM15亦是Wnt的靶基因，在结肠癌细胞中形成正反馈环路。TRIM15在结直肠癌中高表达，并与β-连环蛋白呈正相关。更重要的是，Axin1蛋白水平及其聚合的同步升高可协同诱导凋亡。综上所述，本研究揭示了Axin1聚合的重要调控机制，并提示靶向TRIM15通过抑制Wnt信号可为结直肠癌提供潜在治疗策略。

### 第二部分 AI 大师评价

本研究阐明了TRIM15通过干扰Axin1聚合促进Wnt信号激活与结直肠癌生长的机制。研究者采用分子互作分析、基因操作及小鼠模型验证TRIM15的肿瘤促进作用。其发现TRIM15是Wnt的下游靶基因，构成正反馈环路，为理解Wnt信号调控提供了新视角。该研究创新性地揭示了Axin1聚合调控的新机制，提示靶向TRIM15或为结直肠癌精准治疗的新方向，但其治疗靶点可行性仍需进一步临床验证。

---

## 15. Fbxo2通过调控YTHDF2的泛素化与降解抑制前列腺癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41461633)
**期刊：** Cell death & disease
**PMID：** 41461633
**DOI：** 10.1038/s41419-025-08396-0

### 第一部分 原文与翻译

**英文原标题：** Fbxo2 suppresses prostate cancer progression by regulating YTHDF2 ubiquitination and degradation.

> **英文摘要：**
> Deregulation of E3 ubiquitin ligases is associated with increased proliferation and metastasis in prostate cancer (PCa); however, the underlying mechanisms remain largely unclear. This study aimed to explore the role of Fbxo2, a SKP1-Cullin-F-box (SCF) E3 ubiquitin ligase, in PCa progression. Analysis of prostate tissue samples revealed that Fbxo2 is downregulated in PCa, and higher Fbxo2 expression correlates with better patient prognosis. Functional assays conducted both in vitro and in vivo demonstrated that Fbxo2 reduces cell proliferation and metastasis in PCa. Using co-immunoprecipitation mass spectrometry (co-IP-MS), co-IP, western blotting, and ubiquitin assays, we identified that m6A reader YTHDF2, an oncoprotein that is upregulated in PCa, was a substrate of Fbxo2-mediated degradation. Notably, Fbxo2 mutants lacking the C-terminal region were less effective in promoting YTHDF2 ubiquitination and destruction. Furthermore, lysine 286 (K286) of YTHDF2 was identified as the key ubiquitination site. A series of rescue experiments revealed that silencing or overexpressing YTHDF2 modulated the effects of Fbxo2 knockdown or overexpression, confirming their functional interplay. Mechanistically, YTHDF2 enhanced the PCa progression and metastasis by modulating the m6A methylation of CDKN1C mRNA. Together, these findings suggest that Fbxo2 axis may serve as a potential prognostic marker and therapeutic target in PCa.

> **中文摘要：**
> E3泛素连接酶的失调与前列腺癌（PCa）中增殖和转移的增加相关，但其潜在机制仍不清楚。本研究旨在探索Fbxo2（SKP1-Cullin-F-box复合物的一种E3泛素连接酶）在PCa进展中的作用。对前列腺组织样本的分析显示，Fbxo2在PCa中下调，其高表达与患者较好的预后相关。体内外功能实验表明，Fbxo2可减少PCa细胞的增殖和转移。通过免疫共沉淀质谱（co-IP-MS）、免疫共沉淀、Western blot及泛素化实验，研究者发现m6A识别蛋白YTHDF2（在PCa中上调的致癌蛋白）是Fbxo2介导降解的底物。值得注意的是，缺失C末端结构域的Fbxo2突变体在促进YTHDF2泛素化和降解方面的能力较弱。此外，YTHDF2的赖氨酸286（K286）被确定为关键的泛素化位点。一系列补救实验显示，沉默或过表达YTHDF2可调节Fbxo2敲低或过表达的效应，证实了二者之间的功能相互作用。从机制上看，YTHDF2通过调控CDKN1C mRNA的m6A甲基化促进PCa的进展和转移。综上，这些研究结果提示，Fbxo2通路可能作为PCa的潜在预后标志物和治疗靶点。

### 第二部分 AI 大师评价

该研究聚焦于E3泛素连接酶Fbxo2在前列腺癌中的功能机制，利用组织分析与体内外实验揭示了Fbxo2抑制PCa细胞增殖与转移的作用。作者通过蛋白互作与泛素化实验确定YTHDF2是Fbxo2介导降解的底物，并定位了关键泛素化位点K286。此外，功能补救实验证实Fbxo2与YTHDF2在调控肿瘤进展中的串联关系。研究创新地将泛素化机制与m6A甲基化网络联系起来，但仍需进一步探索其在临床中的可转化潜力。

---

## 16. 系统综述与荟萃分析：CAR-T 与双特异性抗体作为滤泡性淋巴瘤三线及以上治疗的比较

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41461632)
**期刊：** Blood cancer journal
**PMID：** 41461632
**DOI：** 10.1038/s41408-025-01439-x

### 第一部分 原文与翻译

**英文原标题：** Systematic review and meta-analysis: CAR-T vs bispecific antibody as third or later-line therapy for follicular lymphoma.

> **英文摘要：**
> There is currently no clear consensus on the standard of care for relapsed or refractory follicular lymphoma (FL) beyond third-line therapy, where both anti-CD19 CAR-T-cell therapy (CAR-T) and CD3×CD20 bispecific antibodies (BsAbs) have demonstrated efficacy. This study aimed to examine their efficacy and toxicity profiles. Relevant studies published between January 2010 and June 2025 were identified through major databases. Of 3960 records screened, 12 studies met the inclusion criteria-7 involving CAR-T and 5 involving BsAbs. The pooled overall response rate (ORR) and complete response rate (CRR) were 93% and 82% for CAR-T, compared with 82% and 67% for BsAbs (p = 0.0002 and p = 0.005, respectively). Among patients with POD24, the CRR was 75% for CAR-T and 69% for BsAbs (p = 0.56). This translated into improved progression-free survival (PFS) with CAR-T: 6-month, 1-year and 3-year PFS rates were 85%, 74% and 54%, respectively, compared with 74%, 62%, and 42% for BsAbs (p = 0.006, p = 0.002 and p = 0.009, respectively). A trend toward higher 3-year overall survival (OS) was observed with CAR-T (80%) versus BsAbs (73%) (p = 0.48). Grade ≥3 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred more frequently with CAR-T (8% vs. 0%, p = 0.04), whereas grade ≥3 infections were numerically higher with BsAbs (17% vs. 9%, p = 0.31). One-year non-relapse mortality (NRM) was similar between groups at 3%. Overall, CAR-T demonstrated potentially higher efficacy in this non-comparative meta-analysis, while the two therapies exhibited noticeable differences in toxicity profiles.

> **中文摘要：**
> 目前，对于复发或难治性滤泡性淋巴瘤（FL）在三线治疗之后的标准治疗尚无明确共识，其中抗CD19 CAR-T细胞治疗（CAR-T）和CD3×CD20双特异性抗体（BsAbs）均已显示出疗效。本研究旨在评估两者的疗效及毒性特征。研究通过主要数据库检索2010年1月至2025年6月间发表的相关文献。在筛选的3960篇文献中，有12项研究符合纳入标准：其中7项涉及CAR-T，5项涉及BsAbs。合并的总体缓解率（ORR）和完全缓解率（CRR）分别为CAR-T的93%和82%，而BsAbs分别为82%和67%（p=0.0002和p=0.005）。在POD24患者中，CAR-T的CRR为75%，BsAbs为69%（p=0.56）。这转化为CAR-T组更优的无进展生存期（PFS）：6个月、1年和3年的PFS率分别为85%、74%和54%，而BsAbs组分别为74%、62%和42%（p=0.006、p=0.002和p=0.009）。在总体生存（OS）方面，CAR-T组3年OS率为80%，BsAbs组为73%，呈现CAR-T更高趋势（p=0.48）。3级及以上免疫效应细胞相关神经毒性综合征（ICANS）在CAR-T组更常见（8% vs. 0%，p=0.04）；而3级及以上感染在BsAbs组略高（17% vs. 9%，p=0.31）。两组1年非复发死亡率（NRM）均为3%，相似。总体而言，在本次非直接比较的荟萃分析中，CAR-T显示出潜在更高的疗效，而两种疗法在毒性谱方面存在明显差异。

### 第二部分 AI 大师评价

本研究通过系统综述和荟萃分析比较了CAR-T与双特异性抗体在滤泡性淋巴瘤三线及以上治疗中的疗效与安全性。结果显示CAR-T在总体缓解率、完全缓解率及无进展生存方面均优于双特异性抗体，而后者感染相关毒性略高。两者总体生存率差异不显著。该研究为晚期滤泡性淋巴瘤的治疗决策提供了证据支持，但由于为非直接比较性分析，其结论仍需前瞻性研究进一步验证。

---

## 17. 布伦妥昔单抗维多汀与纳武利尤单抗联合化疗用于非体积性、早期经典型霍奇金淋巴瘤的研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460964)
**期刊：** Blood
**PMID：** 41460964
**DOI：** 10.1182/blood.2025030190

### 第一部分 原文与翻译

**英文原标题：** Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

> **英文摘要：**
> Most patients with early-stage classical Hodgkin lymphoma (cHL) are treated with doxorubicin, bleomycin, vinblastine, and dacarbazine with or without radiation therapy, although studies are now evaluating the incorporation of novel agents paired with abbreviated chemotherapy. We present the efficacy and safety of brentuximab vedotin (BV) and nivolumab in combination with doxorubicin and dacarbazine (AN+AD) in patients with early-stage cHL. In this phase 2 study, patients with non-bulky (<10 cm) Ann Arbor stage I or II cHL received 4 cycles of AN+AD. The primary endpoint was complete response (CR) rate at end of treatment (EOT) by investigator. At the time of this analysis, 154 patients received ≥1 dose of AN+AD. The objective response rate at EOT was 96% (95% CI, 91.7-98.6), and the CR rate was 92% (95% CI, 86.0-95.4). In the favorable (n=56) and unfavorable (n=97) subgroups, CR rates were 95% (95% CI, 85.1-98.9) and 91% (95% CI, 83.1-95.7), respectively. The proportion of patients with duration of CR of at least 2 years was 96% (95% CI, 90.9-98.4). At a median follow-up of 27.9 months, the estimated 2-year PFS rate was 97% (95% CI, 92.0-98.8). Any-grade and grade ≥3 treatment-emergent adverse events occurred in 99% and 44% of patients, respectively; no events of febrile neutropenia were reported. Any-grade treatment-emergent immune-mediated adverse events occurred in 22% of patients. One disease-related death was reported after the safety reporting period. Results from this study support the use of BV and nivolumab in combination with limited chemotherapy in patients with non-bulky, early-stage cHL. ClinicalTrials.gov: NCT03646123.

> **中文摘要：**
> 大多数早期经典型霍奇金淋巴瘤（cHL）患者通常接受阿霉素、博来霉素、长春花碱和达卡巴嗪联合或不联合放疗治疗，然而，近期的研究正在评估将新型药物与缩短的化疗方案相结合的可行性。我们报告了布伦妥昔单抗维多汀（BV）和纳武利尤单抗与阿霉素及达卡巴嗪（AN+AD）联合用于早期cHL患者的疗效与安全性。在这项Ⅱ期研究中，非体积性（<10 cm）Ann Arbor分期I或II期cHL患者接受了4个疗程的AN+AD治疗。主要终点为研究者评估的治疗结束（EOT）时的完全缓解（CR）率。在本次分析时，共有154例患者接受了至少1次AN+AD治疗。EOT时的客观缓解率为96%（95% CI，91.7–98.6），CR率为92%（95% CI，86.0–95.4）。其中，预后良好组（n=56）与预后不良组（n=97）的CR率分别为95%（95% CI，85.1–98.9）和91%（95% CI，83.1–95.7）。CR持续时间达到或超过2年的患者比例为96%（95% CI，90.9–98.4）。在中位随访27.9个月时，估计的2年无进展生存率（PFS）为97%（95% CI，92.0–98.8）。任何级别及≥3级治疗相关不良事件的发生率分别为99%和44%；未报告发热性中性粒细胞减少事件。任何级别的免疫介导不良事件发生于22%的患者。安全报告期后报告1例疾病相关死亡。本研究结果支持在非体积性早期cHL患者中，将BV和纳武利尤单抗联合有限化疗作为一种可行治疗策略。临床试验注册号：NCT03646123。

### 第二部分 AI 大师评价

本研究是一项Ⅱ期临床试验，评估布伦妥昔单抗维多汀与纳武利尤单抗联合阿霉素及达卡巴嗪治疗非体积性早期经典型霍奇金淋巴瘤的疗效与安全性。结果显示，方案具有极高的完全缓解率和2年无进展生存率，且耐受性良好。研究为免化联合有限化疗在早期cHL中的应用提供了有力证据。其创新在于将抗CD30抗体偶联药物与PD-1抑制剂联合进入一线治疗尝试，但局限在于缺乏随机对照及长期随访数据。

---

## 18. 在小鼠移植物抗宿主病过程中，肠球菌诱导肠上皮细胞表达 MHC-II 分子。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460962)
**期刊：** Blood
**PMID：** 41460962
**DOI：** 10.1182/blood.2024028248

### 第一部分 原文与翻译

**英文原标题：** Enterococcus induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease.

> **英文摘要：**
> Intestinal Enterococcus domination has been associated with an increased risk of mortality by acute graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation (allo-HCT), a curative-intent treatment for patients with hematologic malignancies. In this study, we investigate the interactions between Enterococcus and the intestinal epithelium as a mechanism to aggravate GVHD. We observed that endogenous intestinal Enterococcus outgrowth was associated with increased GVHD mortality and major histocompatibility complex class II (MHC-II) expression by intestinal epithelial cells (IECs) in the colon in an MHC-disparate mouse model of GVHD. Monocolonization of non-transplanted gnotobiotic mice with E. faecalis was sufficient to induce colonic MHC-II expression. Conversely, select species within the genus Enterococcus, as well as a consortium of four anaerobic commensal bacteria including Blautia producta, did not affect colonic MHC-II expression in gnotobiotic mice. In addition, E. faecalis colonization also induced inflammatory responses in CD4+ T cells and NK cells from the colonic lamina propria, the two main sources of interferon-gamma production that drives MHC-II expression in non-professional antigen-presenting cells. We further explored the potential therapeutic benefit of establishing colonization resistance against E. faecalis through administration of a lantibiotic-producing B. producta strain after allo-HCT. Colonization of transplanted mice with a consortium of commensal bacteria containing the lantibiotic-producing B. producta strain prevented intestinal Enterococcus domination post-transplant and improved GVHD survival. Our results demonstrate a potential mechanism by which Enterococcus aggravates GVHD through increased MHC-II expression in the intestinal epithelium. Targeting the Enterococcus-epithelium-MHC-II axis thus presents a therapeutic opportunity to prevent lethal GVHD.

> **中文摘要：**
> 肠道肠球菌的优势定植已被证实与异基因造血干细胞移植（allo-HCT）后急性移植物抗宿主病（GVHD）导致的死亡风险增加相关，后者是一种针对血液系统恶性肿瘤患者的治愈性治疗方式。在本研究中，我们探讨了肠球菌与肠上皮之间的相互作用，作为加重 GVHD 的一种潜在机制。我们观察到，在一个 MHC 不匹配的小鼠 GVHD 模型中，内源性肠道肠球菌的过度生长与 GVHD 死亡率升高及结肠肠上皮细胞（IECs）中主要组织相容性复合体 II 类（MHC-II）分子的表达增加有关。使用 E. faecalis 对未移植的无菌小鼠进行单菌定植，即足以诱导结肠 MHC-II 表达。相反，部分肠球菌属的其他种类，以及包括 Blautia producta 在内的四种厌氧共生菌联合体，并未在无菌小鼠中影响结肠 MHC-II 的表达。此外，E. faecalis 定植还诱发了结肠固有层中 CD4+ T 细胞和 NK 细胞的炎症反应，这两类细胞是非专业抗原呈递细胞中驱动 MHC-II 表达的主要干扰素-γ（IFN-γ）来源。我们进一步探讨了在 allo-HCT 后通过给予产生类菌肽的 B. producta 菌株来建立对 E. faecalis 的定植抵抗是否具有潜在治疗价值。用含有该类菌肽产生型 B. producta 菌株的共生菌联合体定植移植后小鼠，可防止移植后肠道肠球菌优势定植，并改善了 GVHD 存活率。我们的结果揭示了肠球菌通过增强肠上皮 MHC-II 表达而加重 GVHD 的潜在机制。因此，靶向“肠球菌–上皮–MHC-II”轴可能为预防致死性 GVHD 提供新的治疗策略。

### 第二部分 AI 大师评价

本研究聚焦肠球菌在异基因造血干细胞移植后加重 GVHD 的机制，揭示其通过诱导肠上皮 MHC-II 表达促进炎症反应。作者采用无菌小鼠单菌定植及共生菌群重建实验，验证了 E. faecalis 的致病性及特异性。研究进一步表明，通过类菌肽产生型 Blautia producta 建立肠道定植抵抗，可显著改善 GVHD 生存结局。该研究创新性地提出了“肠球菌–上皮–MHC-II”轴作为 GVHD 治疗靶点，为微生物调控策略提供了实验依据，虽仍需临床验证，但机制透彻且具转化潜力。

---

## 19. NUTM1重排白血病的综合分子与功能分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460961)
**期刊：** Blood
**PMID：** 41460961
**DOI：** 10.1182/blood.2024026928

### 第一部分 原文与翻译

**英文原标题：** Comprehensive Molecular and Functional Analysis of NUTM1-Rearranged Leukemia.

> **英文摘要：**
> NUTM1-rearrangement (NUTM1-r) defines a significant subset of B-cell acute lymphoblastic leukemia (B-ALL), particularly in infants lacking KMT2A-rearrangements (KMT2A-r), yet its underlying molecular characteristics remain poorly understood. Here, we establish that NUTM1-r leukemia is a discrete entity characterized by a unique transcriptional and epigenetic landscape, notably featuring global DNA hypomethylation, irrespective of the 5' fusion partner. Functional interrogation of NUTM1 fusions reveals a dual oncogenic role: they drive commitment towards the B-lymphoid lineage while concurrently conferring potent leukemic stem cell properties. Strikingly, expression of a representative fusion, BRD9-NUTM1, is sufficient to induce serially-transplantable prepro-B-like leukemia in vivo, faithfully recapitulating the key molecular and immunophenotypic features of human NUTM1-r B-ALL. Mechanistically, NUTM1 fusions establish an aberrant chromatin state, marked by global enhancement of H3K27 acetylation and the creation of distinctive open chromatin regions that co-opt both B-lineage and stemness-related transcriptional programs, including those involving NF-κB and posterior HoxA genes. In stark contrast to resistant KMT2A-r leukemias, NUTM1-r leukemic cells exhibit a profound sensitivity to chemotherapy. This vulnerability is mechanistically linked to the leukemia's dependence on active transcription. Our findings delineate the unique molecular profile of NUTM1-r leukemias, revealing specific vulnerabilities that rationalize their favorable clinical outcomes and suggest opportunities for modified therapeutic strategies.

> **中文摘要：**
> NUTM1重排（NUTM1-r）定义了B细胞急性淋巴细胞白血病（B-ALL）的一个重要亚型，特别是在缺乏KMT2A重排（KMT2A-r）的婴儿病例中，但其潜在的分子特征仍缺乏深入理解。在本研究中，我们确立了NUTM1-r白血病是一种独立的实体，其特征在于独特的转录和表观遗传图谱，显著表现为不论5'融合伴侣为何，均存在全局DNA低甲基化。对NUTM1融合的功能研究揭示了其双重致癌作用：一方面推动向B淋巴系分化倾向，另一方面赋予强大的白血病干细胞特性。值得注意的是，代表性融合基因BRD9-NUTM1的表达足以在体内诱导可连续移植的前前B样白血病，忠实地再现人类NUTM1-r B-ALL的关键分子及免疫表型特征。从机制上看，NUTM1融合建立了一种异常的染色质状态，其特征为H3K27乙酰化的全局增强以及特殊开放染色质区的形成，这些区域协同调动了B系及干性相关的转录程序，包括NF-κB通路及后部HoxA基因。与耐药的KMT2A-r白血病形成鲜明对比，NUTM1-r白血病细胞对化疗表现出显著敏感性。这种易感性在机制上与白血病对活跃转录的依赖密切相关。我们的研究描绘了NUTM1-r白血病独特的分子特征，揭示了特定的脆弱环节，从而解释了其良好的临床预后，并提示了潜在的治疗优化方向。

### 第二部分 AI 大师评价

本研究系统揭示了NUTM1重排白血病的分子与功能学特征，明确其为独立的生物学实体。作者通过转录组与表观遗传分析发现NUTM1融合导致全局DNA低甲基化和H3K27乙酰化增强，从而激活B系分化及干性基因程序。功能实验验证了BRD9-NUTM1融合可在体内诱导可移植白血病模型，具有强烈的实验说服力。研究创新性地揭示了NUTM1-r白血病的化疗敏感性及其机制基础，为临床预后解释和个体化治疗提供了新思路，但其潜在异质性及长期转化效应仍需进一步探讨。

---

## 20. Gαs与Hedgehog信号通路互作的解析揭示了针对Hedgehog依赖性肿瘤的治疗新机遇

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460725)
**期刊：** Cancer research
**PMID：** 41460725
**DOI：** 10.1158/0008-5472.CAN-25-1109

### 第一部分 原文与翻译

**英文原标题：** Dissection of Gαs and Hedgehog Signaling Crosstalk Reveals Therapeutic Opportunities to Target Hedgehog-Dependent Tumors.

> **英文摘要：**
> Basal cell carcinoma (BCC), the most common human cancer, is driven by hyperactivation of the Hedgehog pathway mediated by Smoothened (SMO) signaling and GLI transcription. Gαs and protein kinase A (PKA) negatively regulate Hedgehog signaling, offering a potential alternative BCC development and treatment pathway. Here, using histology alongside bulk and single-cell RNA sequencing, we found that mouse BCC-like tumors that originate from Gαs pathway inactivation are highly similar to those driven by canonical Hedgehog signaling induced by constitutive SMO activation. Both pathways led to expansion of basal stem cells in the skin, with tumor cells clustering in two distinct populations with markers for touch-dome and isthmus stem cell-like cells. Interestingly, mutations that reduce Gαs and PKA activity were present in human BCC. Tumors from Gαs pathway inactivation were independent of the canonical Hedgehog regulators SMO and GPR161, establishing them as SMO-independent oncogenic Hedgehog signaling models. Finally, activation of the Gαs-coupled adenosine 2B receptor with BAY60-6583 counteracted oncogenic SMO, reducing Hedgehog signaling and tumor growth. Together, these findings offer a potential therapeutic strategy for BCC.

> **中文摘要：**
> 基底细胞癌（BCC）是最常见的人类癌症，其发生由Smoothened（SMO）信号和GLI转录介导的Hedgehog通路的过度激活驱动。Gαs和蛋白激酶A（PKA）对Hedgehog信号具有负向调控作用，为BCC的发生与治疗提供了一种潜在的替代通路。在本研究中，通过组织学分析结合整体及单细胞RNA测序，我们发现由Gαs通路失活所起源的小鼠BCC样肿瘤与由持续SMO激活诱导的典型Hedgehog信号驱动的肿瘤在分子特征上高度相似。两种通路均导致皮肤基底干细胞的扩增，肿瘤细胞聚类为两个具有触觉丘和峡部干细胞样标记的不同群体。有趣的是，在人类BCC中检测到降低Gαs和PKA活性的突变。由Gαs通路失活引起的肿瘤不依赖经典的Hedgehog调控因子SMO和GPR161，从而建立了一种SMO非依赖性致癌性Hedgehog信号模型。最后，通过BAY60-6583激活Gαs偶联的腺苷2B受体可拮抗致癌性SMO，抑制Hedgehog信号并减少肿瘤生长。综上，这些发现为BCC提供了一种潜在的治疗策略。

### 第二部分 AI 大师评价

本研究旨在系统解析Gαs与Hedgehog信号通路之间的互作机制，揭示其在基底细胞癌中的致癌潜能及治疗价值。作者利用组织学及多层次转录组学手段，发现Gαs通路失活可独立于SMO激活Hedgehog信号，构成新的致癌轴。进一步通过靶向Gαs偶联受体实现信号抑制，为克服SMO依赖性耐药提供了新思路。研究创新性地定义了SMO非依赖性Hedgehog致癌模型，但其临床转化仍需验证。

---

## 21. 细胞外囊泡介导的 O-GlcNAcase 转移驱动神经元程序性坏死以促进胆囊癌神经周围侵犯

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460724)
**期刊：** Cancer research
**PMID：** 41460724
**DOI：** 10.1158/0008-5472.CAN-25-2237

### 第一部分 原文与翻译

**英文原标题：** Extracellular Vesicle-Mediated O-GlcNAcase Transfer Drives Neuronal Necroptosis to Facilitate Gallbladder Cancer Perineural Invasion.

> **英文摘要：**
> Peripheral nerve invasion (PNI) is an early and decisive step in gallbladder cancer (GBC) progression that strongly predicts poor post-surgical outcome. The tumor-neuron interactions that drive PNI could represent potential targets and biomarkers to improve treatment of GBC. Here, we demonstrated that GBC provoked necroptosis of neurons to enable PNI. GBC cells transferred extracellular vesicles (EVs) containing O-GlcNAcase (OGA) to neurons, which activated RIPK1-dependent necroptosis. Mechanistically, EV-derived OGA suppressed RIPK1 glycosylation while enhancing its phosphorylation, thereby activating the RIPK1/RIPK3/MLKL axis to trigger neuronal necroptosis. Subsequent neuronal release of HMGB1 engaged RAGE on GBC cells, establishing a loop that accelerated PNI. Moreover, the RAGE antagonist FPS-ZM1 synergized with gemcitabine to suppress tumor progression. Collectively, these findings uncover an EV-mediated crosstalk between GBC cells and neurons in which RIPK1-dependent necroptosis and its effector HMGB1 drive PNI, positioning the HMGB1-RAGE axis as a tractable therapeutic target.

> **中文摘要：**
> 神经周围侵犯（PNI）是胆囊癌（GBC）进展过程中的早期且决定性步骤，能够强烈预测术后不良结局。驱动 PNI 的肿瘤–神经元相互作用可能代表改善 GBC 治疗的潜在靶点和生物标志物。在本研究中，我们证明 GBC 可诱导神经元发生程序性坏死（necroptosis）以实现 PNI。GBC 细胞将含有 O-GlcNAcase（OGA）的细胞外囊泡（EVs）转移至神经元，激活了依赖 RIPK1 的程序性坏死。从机制上看，EV 来源的 OGA 抑制了 RIPK1 的糖基化并增强其磷酸化，从而激活 RIPK1/RIPK3/MLKL 轴，触发神经元程序性坏死。随后，神经元释放的 HMGB1 与 GBC 细胞上的 RAGE 结合，建立了加速 PNI 的反馈环。此外，RAGE 拮抗剂 FPS-ZM1 与吉西他滨协同抑制肿瘤进展。综上所述，这些发现揭示了一种由 EV 介导的 GBC 细胞与神经元之间的串扰，其中依赖 RIPK1 的程序性坏死及其效应分子 HMGB1 驱动 PNI，从而将 HMGB1–RAGE 轴定位为可干预的治疗靶点。

### 第二部分 AI 大师评价

该研究揭示胆囊癌通过释放携带 O-GlcNAcase 的细胞外囊泡诱导神经元发生依赖 RIPK1 的程序性坏死，从而促进神经周围侵犯。研究在机制层面显示 OGA 调控 RIPK1 的糖基化与磷酸化状态，激活 RIPK1/RIPK3/MLKL 轴，并通过 HMGB1–RAGE 信号形成正反馈环。作者还验证 RAGE 拮抗剂 FPS-ZM1 与吉西他滨的联合效应，呈现潜在治疗价值。总体而言，该研究系统阐明了 GBC–神经元间的新型通讯机制，具有较强创新性，但具体临床转化仍需进一步验证。

---

## 22. C末端截短及融合伴侣决定FGFR3的致癌性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460723)
**期刊：** Cancer research
**PMID：** 41460723
**DOI：** 10.1158/0008-5472.CAN-24-2648

### 第一部分 原文与翻译

**英文原标题：** C-terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3.

> **英文摘要：**
> Genomic alterations affecting components of the fibroblast growth factor (FGF) signaling axis can trigger aberrant pathway activation and tumor development. Genomic truncation of the FGF receptor 2 (FGFR2) exon 18 (E18) disrupts the FGFR2 carboxy-terminal tail (C-tail), acting as a potent driver alteration across multiple tumor types. Here, we analyzed human oncogenomic datasets to reveal that E18 truncations are similarly prevalent in FGFR3, an FGFR2 paralog. FGFR3 E18 truncations primarily occurred due to rearrangements (REs) that involve transforming acidic coiled-coil containing protein 3 (TACC3), resulting in FGFR3ΔE18-TACC3 gene fusions. In contrast to E18-truncated FGFR2, functional in vitro and in vivo examination of Fgfr3 variants demonstrated that the truncation of Fgfr3 E18 is insufficient to promote oncogenic activity in cell lines or in the lungs and mammary glands of mice. Only the combination of an Fgfr3 E18 truncation with a RE partner gene that encodes a receptor-dimerizing domain resulted in the development of tumors, which were sensitive to FGFR inhibition. Overall, these findings suggest that patients with cancers that are positive for rearranged FGFR3 resulting in E18 truncation and a fusion to dimerizing partners should be considered for FGFR-targeted therapies.

> **中文摘要：**
> 影响成纤维细胞生长因子（FGF）信号轴组分的基因组改变可引发异常的通路激活和肿瘤发生。成纤维细胞生长因子受体2（FGFR2）第18外显子（E18）的基因截短可破坏FGFR2的羧基末端尾部（C尾），在多种肿瘤类型中充当强有力的驱动突变。在本研究中，我们分析了人类肿瘤基因组数据集，发现FGFR2的旁系同源物FGFR3中E18截短同样普遍。FGFR3 E18截短主要由涉及酸性螺旋卷曲蛋白3（TACC3）的重排（REs）引起，从而产生FGFR3ΔE18-TACC3基因融合。与E18截短的FGFR2不同，体外和体内对Fgfr3变体的功能研究表明，Fgfr3 E18的截短本身不足以在细胞系或小鼠的肺部及乳腺中促进肿瘤发生。只有当Fgfr3 E18截短与编码受体二聚化结构域的重排伴侣基因结合时，才会诱导肿瘤形成，而这类肿瘤对FGFR抑制敏感。总体而言，这些发现提示，携带FGFR3重排导致E18截短并融合至二聚化伴侣基因的癌症患者，应考虑接受针对FGFR的靶向治疗。

### 第二部分 AI 大师评价

该研究旨在解析FGFR3基因C末端截短及其融合伴侣在致癌性中的决定性作用。通过多维度的肿瘤基因组数据分析与体内外功能实验，作者发现单一E18截短不足以诱导FGFR3驱动的肿瘤形成，唯有与具二聚化功能的融合伴侣结合时才表现出致癌活性。研究揭示了FGFR3结构-功能耦合的新机制，为精准识别可从FGFR靶向治疗受益的患者提供了强有力的分子依据。其创新性在于比较了FGFR2与FGFR3截短的差异性致癌潜能，并阐明了融合伴侣的关键调控作用。

---

## 23. 2024年 Medicare D 部分费用分担政策变动后专科口服抗癌药处方领取率的变化

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460645)
**期刊：** JAMA
**PMID：** 41460645
**DOI：** 10.1001/jama.2025.22134

### 第一部分 原文与翻译

**英文原标题：** Specialty Oral Anticancer Prescription Fill Rates After Medicare Part D Cost-Sharing Changes in 2024.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本研究聚焦于2024年美国Medicare D部分药物保险费用分担政策调整后，专科口服抗肿瘤药物处方的领取率变化。虽然未提供摘要，但从题目可推测研究旨在评估医保政策变动对抗癌药物可及性和患者经济负担的影响。该主题在肿瘤药物经济学和健康政策领域具有重要意义，可能为未来医保制度优化和药价调控提供现实依据。然而，研究结果的具体细节与方法仍待PubMed正式摘要公开后进一步解析。

---

## 24. 父母之爱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41460642)
**期刊：** JAMA
**PMID：** 41460642
**DOI：** 10.1001/jama.2025.22838

### 第一部分 原文与翻译

**英文原标题：** A Parent's Love.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

这篇发表于《JAMA》的作品标题为“父母之爱”，显然是一篇具有温情与人文关怀主题的文章。虽然未提供摘要，但从标题推测，其主要内容可能探讨亲子关系在医学实践、照护伦理或患者心理支持中的意义。此类文章往往意在提醒医疗专业人员关注医学之外的人性层面，强调情感与共情的重要性。该文的创新性在于通过人文叙事方式强化医学人文精神，但局限性是缺乏科学性数据支撑。

---

速递结束，祝您工作愉快！